Macquarie Group LTD Biotechnology

Macquarie Group LTD

$80.3 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
TBPH Theravance Biopharma, Inc.	$750M	$1.86 Million 0.0% of portfolio	208,783	Q3 2024 Reduced 0.34%
OCUL Ocular Therapeutix, Inc	$889M	$1.8 Million 0.0% of portfolio	244,984	Q1 2025 Added 2,222.56%
ACAD Acadia Pharmaceuticals Inc	$3.65B	$1.54 Million 0.0% of portfolio	92,648	Q1 2025 Reduced 11.04%
CRNX Crinetics Pharmaceuticals, Inc.	$1.64B	$1.51 Million 0.0% of portfolio	44,908	Q1 2025 Reduced 0.67%
CGEN Compugen LTD	$134M	$1.49 Million 0.0% of portfolio	1,020,000	Q1 2024 Added 2.0%
COGT Cogent Biosciences, Inc.	$819M	$1.38 Million 0.0% of portfolio	230,000	Q2 2022 New
CMPX Compass Therapeutics, Inc.	$311M	$1.29 Million 0.0% of portfolio	681,544	Q1 2025 New
ARVN Arvinas, Inc.	$403M	$1.26 Million 0.0% of portfolio	180,000	Q1 2025 New
AKRO Akero Therapeutics, Inc.	$2.41B	$1.21 Million 0.0% of portfolio	30,000	Q1 2025 New
RGNX Regenxbio Inc.	$370M	$1.07 Million 0.0% of portfolio	149,000	Q4 2022 Reduced 0.22%
DAWN Day One Biopharmaceuticals, Inc.	$483M	$872,000 0.0% of portfolio	110,000	Q3 2024 Reduced 0.55%
PRQR Pro Qr Therapeutics N.V.	$162M	$824,000 0.0% of portfolio	620,000	Q1 2021 New
CHRS Coherus Bio Sciences, Inc.	$71.5M	$728,000 0.0% of portfolio	899,999	Q1 2024 Added 38.46%
MGNX Macrogenics Inc	$94.6M	$533,000 0.0% of portfolio	420,000	Q4 2022 Reduced 0.12%
ALT Altimmune, Inc.	$206M	$500,000 0.0% of portfolio	100,000	Q2 2024 Added 124.85%
VTYX Ventyx Biosciences, Inc.	$171M	$494,000 0.0% of portfolio	430,000	Q1 2024 New
ARGX Argenx Se	$31.6B	$416,000 0.0% of portfolio	704	Q4 2023 Added 163.67%
RCKT Rocket Pharmaceuticals, Inc.	$255M	$386,000 0.0% of portfolio	58,000	Q4 2022 Reduced 0.54%
CLLS Cellectis S.A.	$101M	$281,000 0.0% of portfolio	226,875	Q3 2020 Added 3.28%
SGMO Sangamo Therapeutics, Inc	$75.1M	$264,000 0.0% of portfolio	400,000	Q3 2024 Reduced 1.88%
ALLO Allogene Therapeutics, Inc.	$204M	$214,000 0.0% of portfolio	146,779	Q4 2022 Reduced 0.4%
AVIR Atea Pharmaceuticals, Inc.	$286M	$209,000 0.0% of portfolio	70,000	Q4 2022 Reduced 2.1%
LEGN Legend Biotech Corp	$7.37B	$181,000 0.0% of portfolio	5,349	Q1 2025 Reduced 22.33%
PBYI Puma Biotechnology, Inc.	$159M	$181,000 0.0% of portfolio	61,255	Q2 2024 Reduced 2.44%
NKTR Nektar Therapeutics	$4.59B	$174,000 0.0% of portfolio	256,385	Q4 2022 Reduced 0.99%
NTLA Intellia Therapeutics, Inc.	$1.03B	$142,000 0.0% of portfolio	20,000	Q4 2022 Reduced 2.34%
NXTC Next Cure, Inc.	$141M	$72,000 0.0% of portfolio	150,000	Q1 2022 Reduced 0.16%
XOMA Xoma Corp	$291M	$69,000 0.0% of portfolio	3,466	Q2 2020 Reduced 36.29%
MRSN Mersana Therapeutics, Inc.	$35M	$51,000 0.0% of portfolio	150,000	Q4 2022 Reduced 2.47%
NVO Novo Nordisk A S	$151B	$45,000 0.0% of portfolio	652	Q1 2025 Added 533.01%
PTGX Protagonist Therapeutics, Inc	$2.7B	$27,000 0.0% of portfolio	566	Q1 2025 New
VYGR Voyager Therapeutics, Inc.	$122M	$19,000 0.0% of portfolio	5,700	Q1 2022 Reduced 7.54%
INVA Innoviva, Inc.	$1.34B	$16,000 0.0% of portfolio	886	Q1 2025 New
KOD Kodiak Sciences Inc.	$290M	$9,000 0.0% of portfolio	3,272	Q1 2025 New
GMAB Genmab A/S	$14.4B	$6,000 0.0% of portfolio	323	Q1 2025 Added 2.87%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.